Orca Bio

Ivan Dimov, Ph.D., CEO and Co-Founder 

Oct. 12 | 11:15am | BlueRock Therapeutics Ballroom

Menlo Park, CA

(Private)

In-person Presentation

Established in 2016, Orca Bio is a clinical-stage biotechnology company developing a pipeline of high-precision allogeneic cell therapy products. Our products are designed to safely and effectively replace a patient’s diseased blood and immune system with a healthy one. The company’s proprietary therapeutic and manufacturing platforms are exclusively licensed from Stanford University. At this past ASH and TCT, we released the results from the first 50 patients of our single arm multicenter trial with our lead product vs. a concurrent comparator for allogeneic transplant patients. Results showed 0% vs. 11% TRM, 3% vs. 46% cGVHD, 10% vs. 30% aGVHD and 75% vs. 31% GRFS. We plan to release our final results of the trial at ASH and are working with the FDA to launch our pivotal trial. We have treated over 150 patients between our lead program and our second product which is already in the clinic.

www.orcabio.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions